Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023

Recommend to a Colleague print

 

Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.

11 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• Highlights of EAN 2026 – Part 2
  July 9, 2026
• Highlights of EAN 2026 – Part 1
  June 30, 2026
• CLINICAL CASES IN NEUROLOGY – A PERIMENOPAUSAL WOMAN WITH MIGRAINE AND HEAD TRAUMA
  May 25, 2026
• CLINICAL CASES IN NEUROLOGY: A 55-y.o. with new MRI lesions
  May 19, 2026
• Reducing PIRA with high-efficacy DMTs in MS
  May 11, 2026

Go back to home page